RENOVORX INC
RNXTNASDAQTrading Snapshot
- Day Range
- $1.14 – $1.17
- 52-Week Range
- $0.70 – $1.45
- Volume
- $2.01B
- Avg Volume
- $1.65B
- Shares Outstanding
- 45.1M
- Next Earnings
- Sep 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $563,000
- P/E Ratio
- -3.4
- P/S Ratio
- 34.8x
- EPS (TTM)
- $-0.32
- Dividend Yield
- 0.00%
Why Investors Own RNXT
- ✓High-growth profile — revenue up +23.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About RENOVORX INC
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press release, Q2